N-[(5aR,6aS,7S,9Z,10aS)-9-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-1,10a,12-trihydroxy-8,10,11-trioxo-5,5a,6,6a,7,8,9,10,10a,11-decahydrotetracen-2-yl]-2-(tert-butylamino)acetamide
Distribution
Plasma protein binding ranges from 71% to 89%. Vd is 7 to 9 L/kg.
Metabolism
Not extensively metabolized.
Elimination
The t ½ is approximately 42 h (multiple dosing). Primary route of elimination is biliary/fecal excretion (59% of dose); glucuronidation and renal excretion are secondary routes (33% of dose excreted in urine, 22% as unchanged tigecycline).
Special Populations
Hepatic Function Impairment
Systemic Cl reduced 25% and t ½ prolonged 23% in patients with moderate hepatic function impairment (Child-Pugh class B); systemic Cl reduced 55% and t ½ prolonged 43% in patients with severe hepatic function impairment (Child-Pugh class C).
Contraceptives, oral
Coadministration may decrease the effectiveness of the oral contraceptive.
Warfarin
Because warfarin Cl may be reduced and plasma levels may be increased, monitor PT or other suitable anticoagulation parameters.
藥品應置於攝氏 15 ~ 25 度乾燥處所；如發生變質或過期，不可再使用。
1. 限下列條件之一使用：
(1)經細菌培養證實有意義之致病菌且對其他抗微生物製劑均具抗藥性或對其他具有感受性抗微生物製劑過敏，而對tigecycline具有感受性 (sensitivity) 之複雜性皮膚及皮膚結構感染或複雜性腹腔內感染症使用。
(2)其他經感染症專科醫師會診，認定需使用之下列感染症：複雜性皮膚及皮膚結構感染、複雜性腹腔內感染、社區感染性肺炎。(100/7/1)
2.申報費用時需檢附會診紀錄或相關之病歷資料。
